千亿·国际(中国)唯一官方网站
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2023.03.30
2022年年度报告
2023.03.30
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2022
2023.03.29
千亿国际:千亿·国际(中国)唯一官方网站 2022年面向专业投资者公开发行公司债券2023年...
2023.03.28
千亿国际:关于子公司签订许可协议的公告
2023.03.28
VOLUNTARY ANNOUNCEMENT ENTERING INTO LICENSE AND DISTRIBUTION AGREEMENT WITH OEP...
2023.03.17
千亿国际:关于依诺肝素钠注射液获得美国药品注册批件的公告
2023.03.17
VOLUNTARY ANNOUNCEMENT “ENOXAPARIN SODIUM INJECTION” OBTAINED ANDA APPROVAL FROM...
2023.03.15
DATE OF BOARD MEETING
2023.02.24
Overseas Regulatory Announcement
2023.02.24
Overseas Regulatory Announcement
第一页
上一页
20
21
22
23
24
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.